Exosome removal as a therapeutic adjuvant in cancer

Aethlon Medical Inc, 8910 University Center Lane, Suite 660, San Diego, CA, 92122, USA. .
Journal of Translational Medicine (Impact Factor: 3.99). 06/2012; 10:134. DOI: 10.1186/1479-5876-10-134
Source: PubMed

ABSTRACT Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth, immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30-100 nm membrane vesicles released by many cells types during normal physiological processes. Tumors aberrantly secrete large quantities of exosomes that transport oncoproteins and immune suppressive molecules to support tumor growth and metastasis. The role of exosomes in intercellular signaling is exemplified by human epidermal growth factor receptor type 2 (HER2) over-expressing breast cancer, where exosomes with the HER2 oncoprotein stimulate tumor growth and interfere with the activity of the therapeutic antibody Herceptin®. Since numerous observations from experimental model systems point toward an important clinical impact of exosomes in cancer, several pharmacological strategies have been proposed for targeting their malignant activities. We also propose a novel device strategy involving extracorporeal hemofiltration of exosomes from the entire circulatory system using an affinity plasmapheresis platform known as the Aethlon ADAPT™ (adaptive dialysis-like affinity platform technology) system, which would overcome the risks of toxicity and drug interactions posed by pharmacological approaches. This technology allows affinity agents, including exosome-binding lectins and antibodies, to be immobilized in the outer-capillary space of plasma filtration membranes that integrate into existing kidney dialysis systems. Device therapies that evolve from this platform allow rapid extracorporeal capture and selective retention of target particles < 200 nm from the entire circulatory system. This strategy is supported by clinical experience in hepatitis C virus-infected patients using an ADAPT™ device, the Hemopurifier®, to reduce the systemic load of virions having similar sizes and glycosylated surfaces as cancer exosomes. This review discusses the possible therapeutic approaches for targeting immune suppressive exosomes in cancer patients, and the anticipated significance of these strategies for reversing immune dysfunction and improving responses to standard of care treatments.

  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) exhibit many functions in biological activities. Recent studies have shown that miRNAs exist outside cells and are transferred between cells. Extracellular miRNAs are protected from ribonucleases found in body fluids through binding to specific proteins or by being encapsulated in lipid bilayer vesicles. Here, we review the mechanisms of the secretion and uptake as well as the functions of extracellular miRNAs, particularly those encapsulated in extracellular vesicles. Extracellular vesicles are related to cancer progression, and some miRNAs in extracellular vesicles are associated with cancer cells. We describe the transfer of cancer-related miRNAs between cancer cells and non-cancerous cells. Finally, we discuss the anticipated applications of miRNAs present in extracellular vesicles in diagnostics and therapeutics.
    Cellular and Molecular Life Sciences CMLS 01/2015; DOI:10.1007/s00018-014-1811-0 · 5.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Intercellular communication is one of the most important factors involved in the maintenance of tissue homeo-stasis. The alteration of intercellular interaction correlates with a lot of human diseases including canceroge-nesis. There are several types of such interconnection. First of all, it is a direct cell-cell contact, as it takes place in epithelium. The disturbance of this communication is expressed as a loss of cell-cell, cell-matrix contacts, distur-bances of cell polarity etc. Another way of intercellular interaction involves mutual influence via paracrine fac-tors produced by corresponding cells. However, there is another kind of information exchange between the cells, namely microvesicular transportation. It was revealed that the exosomes take part in intercellular communication in normal tissues as well as in malignant neoplasia. The present review provides the recent information on the formation of exosomes, their composition and especially the exosome participation in tumor-stromal interactions.
    Biopolymers and Cell 01/2014; 30(6):426-435. DOI:10.7124/bc.0008BC
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extracellular vesicles including exosomes, microvesicles and apoptotic vesicles, are phospholipid bilayer surrounded structures secreted by cells universally, in an evolutionarily conserved fashion. Posttranslational modifications such as oxidation, citrullination, phosphorylation and glycosylation play diverse roles in extracellular vesicle biology. Posttranslational modifications orchestrate the biogenesis of extracellular vesicles. The signals extracellular vesicles transmit between cells also often function via modulating posttranslational modifications of target molecules, given that extracellular vesicles are carriers of several active enzymes catalysing posttranslational modifications. Posttranslational modifications of extracellular vesicles can also contribute to disease pathology by e.g. amplifying inflammation, generating neoepitopes or carrying neoepitopes themselves (Figures 1 and 2). Copyright © 2015 Elsevier Ltd. All rights reserved.
    Seminars in Cell and Developmental Biology 02/2015; DOI:10.1016/j.semcdb.2015.02.012 · 5.97 Impact Factor

Full-text (3 Sources)

Available from
Jun 4, 2014